Top

Breast Cancer Research and Treatment

Published in:

Open Access 01-11-2017 | Review

Meta-analysis of tumour burden in pre-operative axillary ultrasound positive and negative breast cancer patients

Authors: Muneer Ahmed, F. Jozsa, R. Baker, I. T. Rubio, J. Benson, M. Douek

Published in: Breast Cancer Research and Treatment | Issue 2/2017

Abstract

Background

Management of the axilla in breast cancer is becoming increasingly conservative. Patients identified with a low axillary nodal burden (two or fewer involved nodes) at sentinel node biopsy (SNB) can avoid completion axillary node clearance (cANC). ‘Fast track’ to ANC in patients with involved nodes on pre-operative ultrasound may be over-treating a subgroup of these patients with low nodal burden, which would have precluded their need for ANC. This systematic review assesses the proportion of patients with involved nodes on pre-operative axillary ultrasound, which would fit low axillary burden criteria.

Methods

Meta-analysis of studies comparing axillary burden of breast cancer patients identified as pre-operative ultrasound negative versus positive was performed. The primary outcome measure was the number of patients with two or fewer involved nodes (macrometastases only). Pooled odds ratio (OR), 95% confidence intervals (CIs), means and probabilities of identifying two or fewer involved nodes versus greater than two were calculated.

Results

Six studies reported the axillary burden in 4271 patients who were either directed straight to ANC or cANC after SNB. There was a significantly greater axillary burden in the ultrasound positive versus negative groups (OR 5.95, 95% CI 5.80–6.11) with mean nodal retrieval values of 2.9 [standard error (SE) 0.2] and 1.6 (SE 0.2) nodes, respectively. Cumulative probabilities identified 78.9% of ultrasound negative and 43.2% of ultrasound positive patients possessed low axillary burden.

Conclusions

Pre-operative ultrasound positive patients have significantly higher axillary burden. However, nearly half do fit the criteria of low axillary burden and could be considered for omission of ANC.

Imoto S, Ochiai A, Okumura C, Wada N, Hasebe T (2006) Impact of isolated tumor cells in sentinel lymph nodes detected by immunohistochemical staining. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol 32(10):1175–1179

Galimberti V, Botteri E, Chifu C, Gentilini O, Luini A, Intra M, Baratella P, Sargenti M, Zurrida S, Veronesi P, Rotmensz N, Viale G, Sonzogni A, Colleoni M, Veronesi U (2012) Can we avoid axillary dissection in the micrometastatic sentinel node in breast cancer? Breast Cancer Res Treat 131(3):819–825CrossRefPubMed

Donker M, van Tienhoven G, Straver ME, Meijnen P, van de Velde CJH, Mansel RE, Cataliotti L, Westenberg AH, Klinkenbijl JHG, Orzalesi L, Bouma WH, van der Mijle HCJ, Nieuwenhuijzen GAP, Veltkamp SC, Slaets L, Duez NJ, de Graaf PW, van Dalen T, Marinelli A, Rijna H, Snoj M, Bundred NJ, Merkus JWS, Belkacemi Y, Petignat P, Schinagl DAX, Coens C, Messina CGM, Bogaerts J, Rutgers EJT (2014) Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol 15(12):1303–1310CrossRefPubMedPubMedCentral

Giuliano AE, McCall L, Beitsch P, Whitworth PW, Blumencranz P, Leitch AM, Saha S, Hunt KK, Morrow M, Ballman K (2010) Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg 252(3):426–432; discussion 432–423

Gill G, Surgeons STGotRACo, Centre NCT (2009) Sentinel-lymph-node-based management or routine axillary clearance? One-year outcomes of sentinel node biopsy versus axillary clearance (SNAC): a randomized controlled surgical trial. Ann Surg Oncol 16(2):266–275CrossRefPubMed

Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Ashikaga T, Weaver DL, Miller BJ, Jalovec LM, Frazier TG, Noyes RD, Robidoux A, Scarth HM, Mammolito DM, McCready DR, Mamounas EP, Costantino JP, Wolmark N, National Surgical Adjuvant B, Bowel P (2007) Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol 8(10):881–888CrossRefPubMed

Mansel RE, Fallowfield L, Kissin M, Goyal A, Newcombe RG, Dixon JM, Yiangou C, Horgan K, Bundred N, Monypenny I, England D, Sibbering M, Abdullah TI, Barr L, Chetty U, Sinnett DH, Fleissig A, Clarke D, Ell PJ (2006) Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC trial. J Natl Cancer Inst 98(9):599–609CrossRefPubMed

Veronesi U, Paganelli G, Viale G, Luini A, Zurrida S, Galimberti V, Intra M, Veronesi P, Robertson C, Maisonneuve P, Renne G, De Cicco C, De Lucia F, Gennari R (2003) A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 349(6):546–553CrossRefPubMed

Zavagno G, De Salvo GL, Scalco G, Bozza F, Barutta L, Del Bianco P, Renier M, Racano C, Carraro P, Nitti D, Trialists G (2008) A randomized clinical trial on sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer: results of the Sentinella/GIVOM trial. Ann Surg 247(2):207–213CrossRefPubMed

10.

Kim T, Giuliano AE, Lyman GH (2006) Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis. Cancer 106(1):4–16CrossRefPubMed

11.

Bedrosian I, Bedi D, Kuerer HM, Fornage BD, Harker L, Ross MI, Ames FC, Krishnamurthy S, Edeiken-Monroe BS, Meric F, Feig BW, Akins J, Singletary SE, Mirza NQ, Hunt KK (2003) Impact of clinicopathological factors on sensitivity of axillary ultrasonography in the detection of axillary nodal metastases in patients with breast cancer. Ann Surg Oncol 10(9):1025–1030CrossRefPubMed

12.

Sahoo S, Sanders MA, Roland L, Pile N, Chagpar AB (2007) A strategic approach to the evaluation of axillary lymph nodes in breast cancer patients: analysis of 168 patients at a single institution. Am J Surg 194(4):524–526CrossRefPubMed

13.

van Wely BJ, de Wilt JH, Francissen C, Teerenstra S, Strobbe LJ (2015) Meta-analysis of ultrasound-guided biopsy of suspicious axillary lymph nodes in the selection of patients with extensive axillary tumour burden in breast cancer. Br J Surg 102(3):159–168CrossRefPubMed

14.

von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP, Initiative S (2007) The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 370(9596):1453–1457CrossRef

15.

Everitt B, Dunn G (1992) Applied multivariate data analysis. Oxford University Press, New York, p xii

16.

Barco I, Chabrera C, Garcia-Fernandez A, Fraile M, Gonzalez S, Canales L, Lain JM, Gonzalez C, Vidal MC, Vallejo E, Deu J, Pessarrodona A, Gimenez N, Garcia Font M (2016) Role of axillary ultrasound, magnetic resonance imaging, and ultrasound-guided fine-needle aspiration biopsy in the preoperative triage of breast cancer patients. Clin Transl Oncol Off Publ Fed Span Oncol Soc Natl Cancer Inst Mex. doi:10.1007/s12094-016-1589-7

17.

Boland MR, Ni Cearbhaill R, Fitzpatrick K, Walsh SM, Evoy D, Geraghty J, Rothwell J, McNally S, O’Doherty A, Quinn CM, McDermott EW, Prichard RS (2016) A positive node on ultrasound-guided fine needle aspiration predicts higher nodal burden than a positive sentinel lymph node biopsy in breast carcinoma. World J Surg 40(9):2157–2162CrossRefPubMed

18.

Boone BA, Huynh C, Spangler ML, Sumkin J, Johnson R, McGuire KP, Soran A, Ahrendt GM (2015) Axillary lymph node burden in invasive breast cancer: a comparison of the predictive value of ultrasound-guided needle biopsy and sentinel lymph node biopsy. Clin Breast Cancer 15(5):e243–e248CrossRefPubMed

19.

Caudle AS, Kuerer HM, Le-Petross HT, Yang W, Yi M, Bedrosian I, Krishnamurthy S, Fornage BD, Hunt KK, Mittendorf EA (2014) Predicting the extent of nodal disease in early-stage breast cancer. Ann Surg Oncol 21(11):3440–3447CrossRefPubMed

20.

Moorman AM, Bourez RL, Heijmans HJ, Kouwenhoven EA (2014) Axillary ultrasonography in breast cancer patients helps in identifying patients preoperatively with limited disease of the axilla. Ann Surg Oncol 21(9):2904–2910CrossRefPubMed

21.

Verheuvel NC, van den Hoven I, Ooms HW, Voogd AC, Roumen RM (2015) The role of ultrasound-guided lymph node biopsy in axillary staging of invasive breast cancer in the post-ACOSOG Z0011 trial era. Ann Surg Oncol 22(2):409–415CrossRefPubMed

22.

Galimberti V, Cole BF, Zurrida S, Viale G, Luini A, Veronesi P, Baratella P, Chifu C, Sargenti M, Intra M, Gentilini O, Mastropasqua MG, Mazzarol G, Massarut S, Garbay JR, Zgajnar J, Galatius H, Recalcati A, Littlejohn D, Bamert M, Colleoni M, Price KN, Regan MM, Goldhirsch A, Coates AS, Gelber RD, Veronesi U, International Breast Cancer Study Group Trial I (2013) Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol 14(4):297–305CrossRefPubMedPubMedCentral

23.

Giuliano AE, Ballman K, McCall L, Beitsch P, Whitworth PW, Blumencranz P, Leitch AM, Saha S, Morrow M, Hunt KK (2016) Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: long-term follow-up from the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 randomized trial. Ann Surg 264(3):413–420CrossRefPubMedPubMedCentral

24.

Lyman GH, Somerfield MR, Bosserman LD, Perkins CL, Weaver DL, Giuliano AE (2016) Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol Off J Am Soc Clin Oncol. doi:10.1200/JOP.2016.019992

25.

Shah AR, Glazebrook KN, Boughey JC, Hoskin TL, Shah SS, Bergquist JR, Dupont SC, Hieken TJ (2014) Does BMI affect the accuracy of preoperative axillary ultrasound in breast cancer patients? Ann Surg Oncol 21(10):3278–3283CrossRefPubMed

26.

http://www.breastsurgeons.org/statements/guidelines/Performance_and_Practice_Guidelines_Breast_Ultrasound.pdf

27.

Caudle AS, Yang WT, Krishnamurthy S, Mittendorf EA, Black DM, Gilcrease MZ, Bedrosian I, Hobbs BP, DeSnyder SM, Hwang RF, Adrada BE, Shaitelman SF, Chavez-MacGregor M, Smith BD, Candelaria RP, Babiera GV, Dogan BE, Santiago L, Hunt KK, Kuerer HM (2016) Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. J Clin Oncol Off J Am Soc Clin Oncol 34(10):1072–1078CrossRef

28.

Donker M, Straver ME, Wesseling J, Loo CE, Schot M, Drukker CA, van Tinteren H, Sonke GS, Rutgers EJ, Vrancken Peeters MJ (2015) Marking axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients: the MARI procedure. Ann Surg 261(2):378–382CrossRefPubMed

29.

Meng Y, Ward S, Cooper K, Harnan S, Wyld L (2011) Cost-effectiveness of MRI and PET imaging for the evaluation of axillary lymph node metastases in early stage breast cancer. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol 37(1):40–46

30.

Cooper KL, Harnan S, Meng Y, Ward SE, Fitzgerald P, Papaioannou D, Wyld L, Ingram C, Wilkinson ID, Lorenz E (2011) Positron emission tomography (PET) for assessment of axillary lymph node status in early breast cancer: a systematic review and meta-analysis. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol 37(3):187–198

31.

Gentilini O, Veronesi U (2012) Abandoning sentinel lymph node biopsy in early breast cancer? A new trial in progress at the European Institute of Oncology of Milan (SOUND: sentinel node vs Observation after axillary UltraSouND). Breast 21(5):678–681CrossRefPubMed

Title: Meta-analysis of tumour burden in pre-operative axillary ultrasound positive and negative breast cancer patients
Authors: Muneer Ahmed
F. Jozsa
R. Baker
I. T. Rubio
J. Benson
M. Douek
Publication date: 01-11-2017
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 2/2017
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-017-4405-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2017

HER2 intratumoral heterogeneity is independently associated with incomplete response to anti-HER2 neoadjuvant chemotherapy in HER2-positive breast carcinoma

Does obesity modify the relationship between physical activity and breast cancer risk?

Rebuttal comments

Randomized trial of vitamin D3 to prevent worsening of musculoskeletal symptoms in women with breast cancer receiving adjuvant letrozole. The VITAL trial

Vascular function in breast cancer survivors on aromatase inhibitors: a pilot study

Tamoxifen therapy benefit for patients with 70-gene signature high and low risk

Keynote webinar | Spotlight on antibody–drug conjugates in cancer